Heidi Hagen

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

A-Alpha Bio, Inc. designs and develops a drug discovery platform. The firm offers AlphaSeq platform. The company was founded by Randolph Lopez and David Younger in 2017 and is headquartered in Seattle, WA.

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102.